Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program

PURPOSE/BACKGROUND: The Phase 3 program for RBP-7000, a once-monthly subcutaneous (SC) extended-release risperidone formulation approved for treatment of schizophrenia, consisted of a double-blind placebo-controlled trial (previously reported) and a 52-week open-label study of monthly RBP-7000 120 m...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Psychopharmacol
Main Authors: Andorn, Anne, Graham, Jay, Csernansky, John, Newcomer, John W., Shinde, Sunita, Muma, Gilbert, Heidbreder, Christian, Fava, Maurizio
Formato: Artigo
Idioma:Inglês
Publicado em: Lippincott Williams & Wilkins 2019
Assuntos:
Original Contributions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6728056/
https://ncbi.nlm.nih.gov/pubmed/31343440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000001076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados